MS is considered an auto-immune disorder. Biopsies of MS lesions of the spinal cord and brain have shown inflammatory white cells. The exact cause is unknown, but at some point in time immune cells are triggered to attack cells in the spine and brain. These cells have receptors that send and receive messages via interleukins. My guess is that leronlimab has the potential to block CCR5 receptors in MS patients, thus reducing the immune response and inflammation that leads to lesions and the complications and permanent damage associated with those lesions.